Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine ...

Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD.

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh ...

The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark ...

Glenmark Pharmaceuticals recalls 14.76 lakh bottles of Atomoxetine Capsules in the US due to impurity concerns.

Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of ...

ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity ...

Glenmark Pharmaceuticals is recalling 15 lakh bottles of Atomoxetine Capsules in the US due to an N-Nitroso Atomoxetine ...